RBM5 and cancer: We evaluated 6 splicing factor mutations commonly observed in cancer, including hotspot mutations in SF3B1K700E, U2AF1S34F, and CRISPR-engineered loss of function in FUBP1, RBM5, RBM10, and ZRSR2 (Fig. 6b, Supplementary Table 9).